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Abstract 
Background: SARS‑CoV‑2 may produce intestinal symptoms that are generally mild, with a small percentage of 
patients developing more severe symptoms. The involvement of SARS‑CoV‑2 in the physiopathology of bowel dam‑
age is poorly known. Transmission electron microscopy (TEM) is a useful tool  that provides an understanding of SARS‑
CoV‑2 invasiveness, replication and dissemination in body cells but information outside the respiratory tract is very 
limited. We report two cases of severe intestinal complications (intestinal lymphoma and ischaemic colitis) in which 
the presence of SARS‑CoV‑2 in intestinal tissue was confirmed by TEM. These are the first two cases reported in the 
literature of persistence of SARS‑CoV‑2 demonstrated by TEM in intestinal tissue after COVID 19 recovery and SARS‑
CoV‑2 nasopharyngeal clearance.
Case presentation: During the first pandemic peak (1st March–30th April 2020) 932 patients were admitted in 
Hospital Universitari Mútua Terrassa due to COVID‑19, 41 (4.4%) required cross‑sectional imaging techniques to assess 
severe abdominal pain and six of them (0.64%) required surgical resection. SARS‑CoV‑2 in bowel tissue was demon‑
strated by TEM in two of these patients. The first case presented as an ileocaecal inflammatory mass which turned 
to be a B‑cell lymphoma. Viral particles were found in the cytoplasm of endothelial cells of damaged mucosa. In situ 
hybridization was negative in tumour cells, thus ruling out an oncogenic role for the virus. SARS‑CoV‑2 remained 
in intestinal tissue 6 months after nasopharyngeal clearance, suggesting latent infection. The second patient had a 
severe ischaemic colitis with perforation and SARS‑CoV‑2 was also identified in endothelial cells.
Conclusions: Severe intestinal complications associated with COVID‑19 are uncommon. SARS‑CoV‑2 was identified 
by TEM in two cases, suggesting a causal role in bowel damage.
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Background
SARS-CoV-2, the aetiological agent of coronavirus dis-
ease 2019 (COVID-19), like many viruses with respira-
tory involvement, can cause gastrointestinal symptoms. 
In the first series, 5% presented nausea, vomiting, and 
diarrhoea [1]. More recent cohorts and meta-analysis 
showed that diarrhoea and digestive symptoms are 
much more frequent, ranging from 8.0 to 61% [2, 3]. 
Different mechanisms of diarrhoea induced by SARS-
CoV-2 have been proposed. One of them is viral inva-
sion of the gastrointestinal mucosal cells through 
attachment to the angiotensin-converting enzyme 
2 (ACE2) [3–5]. This receptor is present in gastric 
mucosal cells, in the enterocytes of the small intes-
tine and colon. It was found colocalizing with SARS-
CoV-2 by confocal microscopy, proving that this virus 
can invade almost the entire gastrointestinal tract [6]. 
The infective capacity of SARS-CoV-2 of the entero-
cyte has been demonstrated, by using transmission 
electron microscopy (TEM), in human small intestinal 
organoids [7] and in tissue samples of one patient with 
rectal cancer that was operated during the incubation 
period [8]. Apart from that, few cases of COVID-19 
with severe intestinal complications have been reported 
[9]. The majority of them occurred in the setting of 
multiorgan failure without having the certainty of to 
what extent the virus had a direct involvement in the 
physiopathology of inflammation.
TEM allows direct visualization of SARS-CoV-2 
in tissues of COVID-19 patients and provides good 
understanding of coronavirus replication in cells. How-
ever, the demonstration of SARS-CoV-2 by TEM out-
side the respiratory tract has been scarcely reported 
[10, 11] and evidences are still lacking in tissues from 
COVID-19 patients.
We report two patients with COVID-19 presenting 
with intestinal complications (one of them with an intes-
tinal lymphoma and the other developing an ischaemic 
colitis) in which the presence of SARS-CoV-2 in endothe-
lial cells of the intestinal tissue was detected by TEM. 
In addition, we demonstrated, for the first time, that 
SARS-CoV-2 remained in a latent status after COVID-19 
recovery by analysing sequential intestinal samples in a 
6-month period. The potential oncogenic role of SARS-
CoV-2 was investigated through In  situ hybridization 
(ISH) for viral sequences in lymphoma cells.
In order to ascertain how often severe intestinal com-
plications occurred in COVID-19 patients we retrospec-
tively reviewed the clinical records of the 932 patients 
admitted to our hospital during the first pandemic peak 
(March 1 to April 30, 2020). During this period, sixty 
abdominal cross-sectional imaging studies due to acute 
abdominal pain were performed in 41 out of 932 (4.4%) 
patients (mean age 68 years ± 13.5 SD, 63.4% men). Six of 
them (0.64%) required surgical resection due to perfora-
tion or obstruction, including the two patients described 
herein in whom SARS-CoV-2 involvement in the bowel 
damage was suspected (Fig. 1).
Cases presentation
The first case was a 58-year-old male  admitted on March 
19, 2020, due to abdominal pain. He had mild hyperten-
sion and dyslipemia. On physical examination, he was 
haemodynamically stable, with 38.5ºC fever and with 
a hard mass in the right iliac fossa without peritonitis. 
Blood tests revealed haemoglobin 11.2 g/dL, normal glu-
cose, platelet and leucocyte counts, normal renal func-
tion, C-reactive protein (CRP) 43.3  mg/L, international 
normalized ratio (INR) 1.3, and D-dimer 1460  ng/mL. 
Basal arterial blood gas (21%) showed the following 
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Fig. 1 COVID‑19 patients operated during the first pandemic peak (from March 1 to April 30, 2020). This figure shows the diagnoses, histological 
and transmission electron microscopic findings of patients operated during the first peak of the pandemic in our hospital
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values: pH 7.41,  pCO2 38 mmHg,  pO2 71 mmHg,  HCO3 
24.1 mmHg, Sat.  O2 94.2%.
An abdominal computed tomography (CT) scan 
showed thickened walls in the ascending colon and cae-
cum extending to the terminal ileum and appendix that 
suggested a neoformative process. Several enlarged 
lymphadenopathies were also found (Fig.  2A). A posi-
tron emission tomography (PET) scan was performed 
with a staging intention, which described an intensely 
hypermetabolic mass with standard uptake value (SUV) 
max31 in the caecum, and hypermetabolic lymphad-
enopathies in the mesenteric area. In addition, PET scan 
reported a poorly defined pulmonary uptake area in 
the right upper and middle lobes and in the left apical 
region (SUVmax7.7). Chest X-ray showed local patchy 
shadowing in the right middle lobe. All these pulmonary 
findings were suggestive of SARS-CoV-2 pneumonia, 
which was confirmed by a nasopharyngeal smear poly-
merase chain reaction (PCR) test. Treatment with oxy-
gen therapy (high-flow mask, venturi type at 28% at 5 
litres) and pharmacological treatment for COVID-19 
were instituted with hydroxychloroquine 200  mg/12  h 
orally (PO), ceftriaxone 1  g/24  h intravenous (IV), 
azithromycin 500  mg/24  h PO and Lopinavir/Ritonavir 
400 mg/100 mg/12 h PO. The treatment schedule did not 
include any corticosteroid agents at any time during hos-
pital admission. The patient underwent clinical recovery, 
disappearance of fever, frank reduction of the abdominal 
mass (Fig. 2B), blood test normalization and pulmonary 
infiltrate improvement. After discharge, a colonoscopy 
was performed on April 15, 2020. An inflammatory mass 
occupying most of the caecal circumference was found, 
and the ileocecal valve was stenotic, preventing passage 
to the ileum (Fig. 2C). Multiple biopsies of the ascending 
Fig. 2 Complementary examinations (CT scan, colonoscopy, light microscopy and transmission electron microscopy) from case 1. A, B Coronal 
contrast‑enhanced computed tomography (CT) scan at the moment of diagnosis (A) and after COVID‑19 treatment (B). Panel A shows luminal 
narrowing and marked wall thickening involving the ascending colon, caecum, and terminal ileum. Panel B shows significant decrease in the wall 
thickening of the colon and terminal ileum, the lymph nodes have also decreased in size and number. C Colonoscopy at the level of the caecum 
reveals a mass of inflammatory appearance that predominantly affects the ileocecal valve, which is stenosed and prevents passage to the terminal 
ileum. D Haematoxylin and eosin staining of colonic biopsies showing abundant granulation tissue with lymphoplasmacytic inflammation and 
vascular proliferation (×200). E Electron micrograph of a portion of an endothelial cell showing several viral particles (red circles) lying apparently 
free in the cytoplasm, all separate from each other. F Close‑up electron micrograph of one of the viral particles in E. The virus surface protrusions 
(red circle) are distinguished from confounding structures, such as ribosomes in tangential sections of the rough endoplasmic reticulum (red arrow), 
by the more geometric, lighter, hollow‑looking appearance of the former
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colon were taken, showing, on light microscopy, abun-
dant granulation tissue with lymphoplasmocytic inflam-
matory infiltrates and macrophages without granuloma 
formation. Immunohistochemical staining ruled out the 
presence of either an infiltrative epithelial neoplasm or a 
lymphoproliferative process (Fig.  2D). Cytomegalovirus 
(CMV) immunostaining was negative. PCR performed 
on formalin-fixed/paraffin-embedded (FFPE) tissue to 
detect atypical mycobacterial infection and SARS-CoV-2 
were also negative.
The rapid improvement in parallel with COVID-19 
recovery raised the suspicion of intestinal inflammation 
induced by SARS-CoV-2. In order to demonstrate this, 
TEM of the colon tissue, retrieved from the FFPE block, 
was performed. On ultrastructural study, viral particles 
characteristic of coronavirus were found. They showed 
the typical outer surface with several spikes all around 
them; rarely were more than ten found per cell, and they 
were well apart from each other. They were found in the 
cytoplasm of endothelial cells, from capillaries and arte-
rioles in the involved mucosa. An electron-lucid area 
around some of these particles made them quite visible at 
low power. They were usually situated in the centre of an 
irregular and apparently empty space resembling rough 
endoplasmic reticulum. This ‘halo’ apparently prevented 
direct contact of the viral particles with cytoplasmic 
organelles (Fig. 2E, F).
During the next 3  months the patient remained afe-
brile and in overall good condition, but he presented 
self-limited episodes of abdominal pain. Two more CT 
scans and colonoscopies showed progressive decrease 
in the size of the inflammatory mass and of the lymph 
nodes, but persistence of predominantly fibrotic stenosis 
of the terminal ileum including the ileocecal valve. Ile-
ocaecal resection was indicated that was performed on 
August 12, 2020 (Fig. 3A). Microscopic examination of a 
surgical specimen showed infiltration of the caecum and 
ileum by a neoplastic lesion with a diffuse growth pat-
tern, formed by atypical, medium to large-sized lympho-
cytes, with scant cytoplasm, irregular nuclei, vesicular 
chromatin and conspicuous nucleoli. These morphologi-
cal features were suggestive of lymphoma. Immunohis-
tochemistry study was performed, showing expression 
for B-Cell markers (CD20, CD79a), as well as expres-
sion for bcl2, CD10, bcl6, LMO2, CD21, MUM1, and 
c-MYC in the neoplastic cells. Staining for CD23 ruled 
out the presence of a dendritic cell network. A high pro-
liferative index (Ki67) was observed (90% in the hotspot 
areas). ISH technique for Epstein-Barr virus was nega-
tive. The tumour was classified as a diffuse large B-cell 
lymphoma (DLBCL), germinal center subtype (accord-
ing to Hans’ algorithm) (Fig.  3B–D). No component of 
low-grade lymphoma was identified. Rearrangements 
of  MYC,  BCL2  and  BCL6  genes were studied by FISH, 
detecting translocations in BCL2 and BCL6, but not in 
MYC. TEM of the lymphoma showed very scanty but 
convincing inclusions. In the endothelial cells of the lym-
phoma blood vessels, after very careful study, particles 
with coronavirus morphology were detected (Fig. 3E, F). 
Finally, an RNA in situ hybridization (RNA-ISH) assay of 
lymphoma and endothelial cells with SARS-CoV-2 was 
performed with negative results (Fig. 4).
The second case was a 38-year-old male patient, with-
out relevant medical history, was admitted on March 
18, 2020 for fever, dry cough, dyspnoea, and non-bloody 
diarrhoea. On physical examination he was haemody-
namically stable and he had fever (39.2ºC) and bilateral 
rhoncus. Initial blood analysis showed normal haemo-
gram, normal glucose, proteins, renal and liver function, 
INR 1.2, and D-Dimer 217  ng/mL. Arterial blood gas 
analysis performed with a high-flow mask (50% venturi 
type at 10 litres) showed pH 7.45,  pCO2 21 mmHg,  pO2 
95  mmHg,  HCO3 19.7  mmHg, and Sat.O2 97%. Chest 
X-ray showed right peripheral patchy shadowing due 
to COVID-19 (Fig.  5A) that was confirmed by positive 
SARS-CoV-2 nasopharyngeal PCR.
Treatment was started with ceftriaxone 1  g/24  h 
IV, azithromycin 500  mg/24  h PO, lopinavir/rito-
navir 400  mg/100  mg/12  h PO, hydroxychloroquine 
200 mg/12 h PO, Interferonβ1b 0.25 mg/mL subcuta-
neously every 48  h and dexamethasone 20  mg/24 IV. 
The patient was transferred to the intensive care unit 
(ICU) due to acute respiratory failure for orotracheal 
intubation and norepinephrine perfusion. He devel-
oped acute renal failure with oliguria of multifactorial 
cause (hypotension, diarrhoea, and rhabdomyolysis). 
After 1-month, mechanical ventilation was withdrawn 
and he was transferred to a conventional ward where 
oral diet was restarted with good tolerance. Control 
chest X-ray showed almost complete disappearance of 
alveolar infiltrates. On May 6, 2020, the patient sud-
denly presented abdominal pain, predominantly in the 
right hemiabdomen with signs of peritonitis, diapho-
resis, and fever (38.5ºC). His status worsened, with 
haemodynamic instability, and respiratory and renal 
failure. An abdominal CT scan was performed, show-
ing a stenosis in the transverse colon and a marked 
thickening of the right colon wall, surrounded by fat 
stranding (Fig.  5B). An emergency right hemicolec-
tomy with terminal ileostomy was performed. Gross 
examination showed the colonic mucosa to have a 
ground cobblestone appearance, focal ulceration, 
and deposition of fibrinoid material. Histologically, 
mucosal necrosis, submucosal oedema, and haemor-
rhage were seen. The transmural ulcer showed gran-
ulation tissue, chronic inflammation, fibrosis, and 
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Fig. 3 Complementary examinations (intestinal resection specimen, light microscopy and transmission electron microscopy) from case 1. A 
The ileocaecal resection specimen showed an ulcerated lesion with fibrosis of the intestinal wall, causing stenosis. B Haematoxylin and eosin 
staining of the surgical specimen showing diffuse large B‑cell lymphoma germinal center subtype. Lymphocytes of medium and large size with 
irregular nuclei, vesicular chromatin, conspicuous nucleoli and mitotic figures were observed (×100). C‑ D Immunohistochemistry of the lesion 
was performed, showing expression for CD20, CD79a, bcl2, CD10, bcl6, LMO2, MUM1, and c‑MYC. The tumour was classified as diffuse large B‑cell 
lymphoma (DLBCL) germinal center subtype. In panel C, CD20 (clone L26, Ventana, Roche, Tucson, AZ, USA) immunohistochemistry is shown 
(×100). In panel D, a high proliferative index (Ki67) (clone 30‑9, Ventana, Roche, Tucson, AZ, USA) was observed (90% in the hotspot areas) (100x). 
E‑ F Electron micrograph of the lymphoma tissue, in which viral particles are highlighted (red circles). E Viral particles (red circle) remained in 
occasional endothelial cells. F In contrast to coronavirus particles (red circle), pinocytotic vesicles (red arrow) have a smooth contour, their cell 
membrane lipid bilayer may be visualized, and they are often arranged in clusters
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steatonecrosis consistent with intestinal ischaemia. 
The adjacent mucosa showed regenerative changes, 
distorted architectural pattern, and mucinous hyper-
plasia. There was no evidence of CMV infection, nor of 
an infiltrative lesion (Fig. 5C, D). PCR for Clostridium 
difficile (CD) was positive in colon samples. A TEM of 
the colon tissue was performed, showing viral particles 
with a morphologic distribution essentially similar to 
those of case 1 (Fig. 5E, F).
After surgery, the patient was readmitted to the ICU 
with septic shock and multiorgan failure. Antibiotic 
treatment was started with wide antibiotic coverage 
(meropenem 500  mg/8  h IV + linezolid 600  mg/12  h 
IV + metronidazole 500  mg/8  h IV + Vancomycin 
125  mg/6  h via nasogastric route + rectal vancomycin 
enemas). Norepinephrine, dobutamine, and hydrocor-
tisone treatment were administered for 96  h. Finally, 
the patient was extubated, and then transferred to a 
conventional ward to continue rehabilitation until June 
4, 2020, when he was discharged from hospital. The 
final diagnoses were bilateral pneumonia secondary 
to COVID-19 and colonic ischaemia with endothelial 
damage related to SARS-CoV-2 (Fig. 6).
Discussion and conclusion
We present the first two cases in the medical literature of 
severe intestinal complications (intestinal lymphoma and 
ischaemic colitis) in which the presence of SARS-CoV-2 
was confirmed by TEM.
Case 1 had predominantly digestive manifestations and 
CT scan was suggestive of a neoplastic process. However, 
the initial negativity of biopsies for malignancy and the 
dramatic and rapid reduction of the inflammatory mass, 
including the size of lymph nodes, in parallel to COVID-
19 resolution, suggested an aetiological role of SARS-
CoV-2 in the intestinal inflammatory process.
As it is known, corticosteroids are very commonly used 
in the treatment of COVID-19 cytokine storm and they 
may also reduce the lymphoma size. But these drugs were 
not administered to our patient. Initial hypothesis is that 
SARS-CoV-2 was a colonizer of the intestinal mucosa 
but the aetiological role of SARS-CoV-2 in the intestinal 
inflammatory process was suggested by the presence of 
viral particles with the characteristic features of coro-
navirus in the cytoplasm of endothelial cells from blood 
vessels in damaged mucosa. Supporting this view, it is 
known that SARS-CoV-2 may cause endothelial dysfunc-
tion and endotheliitis [12–16]. In addition, macrophages 
Fig. 4 Time course of the patient’s 1 (A) main events. This figure shows the main events and complications of the case 1. The first row of the table 
shows the dates of the events, and the first column describes the complementary examinations carried out
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Fig. 5 Complementary examinations (PA Chest X‑ray, CT‑scan, light microscopy and transmission electron microscopy) from case 2. A PA chest 
radiograph shows ground‑glass opacification of bilateral perihilar region and the peripheral middle third of the right hemithorax. B Abdominal 
contrast‑enhanced CT showing a short stenosis of the proximal transverse colon with mild involvement of the pericolic fat and proximal dilation 
of the ascending colon and small intestine (white arrow). C‑D Haematoxylin and eosin staining of the surgical specimen. C Mucosal necrosis, 
haemorrhage, and submucosal oedema were observed (×40). D Transmural ulcer showed abundant granulation tissue, chronic inflammation, 
fibrosis, and steatonecrosis, findings consistent with intestinal ischaemia (×200). E Electron micrograph of the surgical specimen showing virus 
particles (red circle) in an oedematous, damaged endothelial cell. F Low‑power high‑resolution electron micrograph with markedly oedematous 
endothelial cells and pericytes, congested capillaries with red blood cells and platelets, endothelial cell containing enlarged nuclei and active 
nucleoli. All these features are a reflection of endothelial cell stress, damage, and reactive changes
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infiltrating the colonic mucosa, identified in our case by 
light microscopy, could be responsible for the marked 
fibrotic reaction leading to obstructive symptoms that 
appeared early during the follow-up. In this sense, mac-
rophages enriched in genes that promote fibrosis and 
tissue repair have been identified in the lung of patients 
with severe fibrotic complications from COVID-19 [17].
The diagnosis of DLBCL was finally confirmed in the 
resected ileocecal specimen. SARS-CoV-2 invasion of 
the ileocecal mucosa could have induced a local hyperin-
flammatory response. It was suspected that SARS-CoV-2 
had had an oncogenic role, acting as a trigger, as occurs 
with Epstein-Barr virus and other viruses and with other 
types of neoplasms (human herpes virus 8 in Kaposi’s 
sarcoma and human T-cell lymphotropic virus in T-cell 
leukaemia/lymphoma) [18]. To confirm or rule out this 
hypothesis, RNA-ISH of the DLBCL and endothelial cells 
with SARS-CoV-2 probes was performed with negative 
results, excluding an oncogenic role in this case.
It is also noteworthy the persistence of SARS-CoV-2 
particles in the resection specimen 6 months after 
COVID-19 recovery and nasopharyngeal SARS-CoV-2 
clearance, raising the possibility of latent SARS-CoV-2 
infection as it occurs with CMV.
Case 2, in contrast to case 1, had a classical severe 
COVID-19 with predominantly respiratory symptoms, 
requiring ICU support. Severe colonic inflammation with 
perforation was a late complication appearing almost 
2  months after admission. It was initially interpreted in 
the setting of intestinal damage observed in a critically ill 
patient. The aetiology of this entity is diverse and includes 
sepsis and pseudomembranous colitis, as well as systemic 
or local hypoperfusion [19]. Most of these situations con-
curred with our patient’s condition. With respect to posi-
tive PCR for CD in a colonic sample, this was considered 
a contamination [20] but not a true infection, because 
the patient had no diarrhoea at the time of colonic per-
foration. In spite of this, the patient’s status was severe 
enough to warrant wide antibiotic coverage, including 
specific treatment for CD. The presence of SARS-CoV-2 
in endothelial cells and blood vessels of the bowel wall 
gives support to the idea that this virus was one of the 
main aetiological factors for the ischaemic colitis. SARS-
CoV-2 may well act like other viral infections such as 
CMV, giving rise to inflammatory and ischaemic lesions 
of the intestine [21, 22]. In addition, CMV has been rec-
ognized as one of the significant risk factors for CD colo-
nization [23]. Both agents can cause toxic megacolon and 
bowel perforation, leading to a poor prognosis, as was 
probably the case with SARS-CoV-2.
With regard to the TEM images, the spikes of the virus 
particles do resemble ribosomes in tangentially sectioned 
rough endoplasmic reticulum, but ribosomes are much 
more electron-dense, rounded, and occasionally bilo-
bated, so at very high magnification, the two ribosomal 
subunits can be distinguished [11, 24]. Another poten-
tial pitfall, particularly in endothelial cells, is pinocytotic 
vesicles and clathrin-coated exocytotic vesicles. In con-
trast to coronavirus particles, pinocytotic vesicles have 
a smooth contour and are often arranged in clusters. 
Fig. 6 Time course of the patient’s 2 (B) main events. This figure shows the main events and complications of the case 2. The first row of the table 
shows the dates of the events, and the first column describes the complementary examinations carried out
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Clathrin, on the other hand, does not produce prominent 
spikes but rather mild irregularities in the surface of the 
coated vesicle. Thus, careful consideration of this differ-
ential allows for very high sensitivity and specificity of 
electron microscopy in this setting.
The main strengths of this study are firstly the detailed 
description of SARS-CoV-2 intestinal location by TEM 
with special emphasis in the differential diagnosis with 
other cell components such as ribosomes, vesicles and 
multivesicular bodies which are lookalikes of genuine 
coronaviruses. In this sense, the expertise of electron 
microscopists is essential identifying potential ‘decoys’ 
when looking for SARS-CoV-2 [11]; secondly, the dem-
onstration of SARS-CoV-2 persistence but with a 
decreasing number in endothelial cells in sequential sam-
ples taken within the 6 months after COVID-19 infec-
tion, that suggest a latent status. It is also noteworthy the 
presence of SARS-CoV-2 in endothelial cells instead of in 
enterocytes giving support to the concept that intestinal 
damage may be a consequence of blood dissemination, 
and not through direct enterocyte invasion [11]; It seems 
to be particularly true in the patient of ischaemic colitis 
developing a perforation as a late complication 1 month 
after a severe pneumoniae.
By contrast there are some limitations such as the lack 
of SARS-CoV-2 assessment in the stools of the patients at 
admission and during the follow-up and the lack of other 
morphological and complementary in-situ techniques 
demonstrating viral components in the intestine (PCR 
performed on FFPE tissue to detect SARS-CoV-2 was 
negative in case 1).
This last point is a strong limitation of the study, the 
reason why the authors want to be very cautious with the 
interpretation of the reported findings. Molecular detec-
tion of SARS-CoV-2 infection in FFPE samples is possi-
ble but it is known that tissue processing clearly impacts 
the accuracy of PCR analysis [25–27]. First, performing 
PCR on FFPE samples shows lower diagnostic perfor-
mance compared to fresh samples. This may be due to 
either limited test sensitivity or sampling problem. There 
is a possibility of RNA degradation, which is common 
in clinical samples, particularly when specimens are not 
immediately stored in a transfer medium suitable for 
preserving RNA [26, 27]. Second, in summer 2020, time 
of sample collection, rather than working up a protocol 
optimized for FFPE tissue, a PCR kit designed for phar-
yngeal swabs was used instead. However, detection of 
viral RNA and proteins of the virus does not necessar-
ily reflect the presence of intact and infectious particles 
whereas TEM is able to demonstrate assembled virions 
in COVID-19 infected patients. We are aware that cau-
sality cannot be demonstrated only with two cases, but 
the presence of assembled virions of SARS-CoV-2 in the 
endothelial cells of the damaged tissue, confirmed on 
repeated samples over time suggests that could have an 
aetiological role, despite not having been confirmed by 
other methods.
In conclusion, severe intestinal complications are 
infrequent in COVID-19 patients. The cases reported 
herein demonstrated for the first time by TEM the pres-
ence of assembled virions of SARS-CoV-2 in endothelial 
cells of the intestinal mucosa and persistence 6 months 
after COVID-19 acquisition and resolution. A patho-
physiological role of SARS-CoV-2 in intestinal damage is 
suggested as well as persistence of latent infection. Nega-
tive ISH of the DLBCL cells with SARS-CoV-2 probes 
argues against an oncogenic role of SARS-CoV-2.
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